-
Biologics: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?
Review
(1464) Views (482) Full article downloads
Authors: Jürgen Frevert, Dirk Dressler
Published Date December 2010
Volume 2010:4 Pages 325 - 332
DOI: http://dx.doi.org/10.2147/BTT.S14902
Jürgen Frevert1, Dirk Dressler21Merz Pharmaceuticals GmbH, Frankfurt, Germany; 2Department of Neurology, Hannover Medical School, Hannover, Germany
Abstract: Botulinum toxin type A is a high molecular weight protein complex containing active neurotoxin and complexing proteins, the latter of which, it is believed, protect the neurotoxin when in the gastrointestinal tract, and may facilitate its absorption. Comparisons of conventional botulinum toxin type A drugs that include complexing proteins with the complexing protein-free formulation of Xeomin® strongly suggest that complexing proteins do not affect diffusion of the active neurotoxin. Studies of Xeomin have also shown that complexing proteins do not enhance product stability in storage. However, complexing proteins may stimulate antibody development against botulinum toxin type A. Numerous observational studies have been published showing that some patients receiving conventional botulinum toxin may develop neutralizing antibodies, leading to antibody-induced therapy failure. Studies have shown that Xeomin is not associated with the development of neutralizing antibodies in animal models or in patients. In conclusion, complexing proteins do not contribute to the stability of botulinum toxin type A drugs and do not contribute to their therapeutic effects, but may be associated with a secondary nonresponse due to the development of neutralizing antibodies.
Keywords: botulinum toxin type A, neurotoxin, complexing proteins, neutralizing antibodies
Readers of this article also read:
Management of chronic hepatitis C treatment failures: role of consensus interferon
Treatment of immune thrombocytopenic purpura: focus on eltrombopag
New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride
New and emerging treatment approaches to lupus
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase
Gaucher disease: clinical profile and therapeutic developments
Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus
An update on belimumab for the treatment of lupus
The role of stem cells in tumor targeting and growth suppression of gliomas
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Journal Indexing
See where all the Dove Press journals are indexed
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




